Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323042023> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W4323042023 endingPage "784" @default.
- W4323042023 startingPage "777" @default.
- W4323042023 abstract "The prognosis for patients with acute myeloid leukaemia (AML) varies depending on genetic factors. The presence of mutations in the fms-like tyrosine kinase 3 (FLT3) gene is found in approximately 30% of AML patients. Midostaurin, a first-generation multi-targeted tyrosine kinase inhibitor, is the first FLT3 inhibitor approved for the treatment of newly diagnosed AML patients with the FLT3 mutation in combination with standard induction and consolidation chemotherapy. However, as numerous clinical trials have shown, the list of indications for this drug is likely to be extended. Midostaurin can be administered orally, which improves the patient’s comfort during treatment. In general, it has a favourable safety profile, but interactions with other drugs, such as strong CYP3A4 inhibitors or inducers, which are often used in the concomitant therapy of AML patients, may lead to changes in midostaurin plasma concentrations. In consequence, such interactions may increase the toxicity of the treatment or reduce its therapeutic effect. The aim of this review is to summarise the current knowledge on midostaurin, i.e. its mechanisms of actions, dosage, adverse effects, mechanisms of resistance and limitations to its use. Due to the growing importance of the management of drug-drug interactions mediated via cytochrome CYP3A4, the main focus of this study is the pharmacokinetics of midostaurin and the variability of its plasma concentrations. The Authors emphasise therapeutic drug monitoring with midostaurin as a potential method of managing AML patients with FLT3 mutation." @default.
- W4323042023 created "2023-03-04" @default.
- W4323042023 creator A5026613987 @default.
- W4323042023 creator A5058401326 @default.
- W4323042023 creator A5067269840 @default.
- W4323042023 creator A5073926544 @default.
- W4323042023 creator A5082952004 @default.
- W4323042023 date "2023-03-03" @default.
- W4323042023 modified "2023-09-25" @default.
- W4323042023 title "Midostaurin – the First Targeted Therapy Drug for Patients with Acute Myeloid Leukaemia with FLT3 Mutation" @default.
- W4323042023 doi "https://doi.org/10.32383/appdr/159470" @default.
- W4323042023 hasPublicationYear "2023" @default.
- W4323042023 type Work @default.
- W4323042023 citedByCount "0" @default.
- W4323042023 crossrefType "journal-article" @default.
- W4323042023 hasAuthorship W4323042023A5026613987 @default.
- W4323042023 hasAuthorship W4323042023A5058401326 @default.
- W4323042023 hasAuthorship W4323042023A5067269840 @default.
- W4323042023 hasAuthorship W4323042023A5073926544 @default.
- W4323042023 hasAuthorship W4323042023A5082952004 @default.
- W4323042023 hasBestOaLocation W43230420231 @default.
- W4323042023 hasConcept C121608353 @default.
- W4323042023 hasConcept C126322002 @default.
- W4323042023 hasConcept C143998085 @default.
- W4323042023 hasConcept C197934379 @default.
- W4323042023 hasConcept C2776481607 @default.
- W4323042023 hasConcept C2778729363 @default.
- W4323042023 hasConcept C2778820342 @default.
- W4323042023 hasConcept C2780035454 @default.
- W4323042023 hasConcept C2781230642 @default.
- W4323042023 hasConcept C502942594 @default.
- W4323042023 hasConcept C71924100 @default.
- W4323042023 hasConcept C98274493 @default.
- W4323042023 hasConceptScore W4323042023C121608353 @default.
- W4323042023 hasConceptScore W4323042023C126322002 @default.
- W4323042023 hasConceptScore W4323042023C143998085 @default.
- W4323042023 hasConceptScore W4323042023C197934379 @default.
- W4323042023 hasConceptScore W4323042023C2776481607 @default.
- W4323042023 hasConceptScore W4323042023C2778729363 @default.
- W4323042023 hasConceptScore W4323042023C2778820342 @default.
- W4323042023 hasConceptScore W4323042023C2780035454 @default.
- W4323042023 hasConceptScore W4323042023C2781230642 @default.
- W4323042023 hasConceptScore W4323042023C502942594 @default.
- W4323042023 hasConceptScore W4323042023C71924100 @default.
- W4323042023 hasConceptScore W4323042023C98274493 @default.
- W4323042023 hasIssue "6" @default.
- W4323042023 hasLocation W43230420231 @default.
- W4323042023 hasOpenAccess W4323042023 @default.
- W4323042023 hasPrimaryLocation W43230420231 @default.
- W4323042023 hasRelatedWork W1991532189 @default.
- W4323042023 hasRelatedWork W2770565416 @default.
- W4323042023 hasRelatedWork W2791272905 @default.
- W4323042023 hasRelatedWork W2892838729 @default.
- W4323042023 hasRelatedWork W2966283333 @default.
- W4323042023 hasRelatedWork W3029854397 @default.
- W4323042023 hasRelatedWork W3094177542 @default.
- W4323042023 hasRelatedWork W3129254720 @default.
- W4323042023 hasRelatedWork W3201095442 @default.
- W4323042023 hasRelatedWork W4280536749 @default.
- W4323042023 hasVolume "79" @default.
- W4323042023 isParatext "false" @default.
- W4323042023 isRetracted "false" @default.
- W4323042023 workType "article" @default.